Aclaris Therapeutics, Inc. — Director's Dealing 2018

Feb 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2018-02-01

Reporting Person: Ali-Jackson Kamil (Chief Legal Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-01	Stock option (right to buy)	$22.09	A	54000	Acquired	2028-01-31	Common Stock (54000)	Direct
2018-02-01	Restricted stock units	$	A	15500	Acquired		Common Stock (15500)	Direct

Footnotes

F1: The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant.

F2: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.